-
Je něco špatně v tomto záznamu ?
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
P. Harter, G. Bogner, L. Chiva, D. Cibula, N. Concin, C. Fotopoulou, A. Gonzalez-Martin, F. Guyon, V. Heinzelmann-Schwarz, F. Kridelka, S. Mahner, F. Marmé, C. Marth, P. Morice, Z. Novák, A. Papadia, I. Ray-Coquard, M. Redecha, A. Redondo, R....
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články, přehledy
- MeSH
- epiteliální ovariální karcinom patologie MeSH
- hypertermická intraperitoneální peroperační chemoterapie MeSH
- indukovaná hypertermie * metody MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- nádory vaječníků * farmakoterapie patologie MeSH
- prospektivní studie MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Rakousko MeSH
- Švýcarsko MeSH
An international joint statement about the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer was published in 2016, warning about the uncritical use of HIPEC outside controlled studies. This statement has now been updated after the most recent literature was reviewed by the participating study groups and societies. HIPEC became a treatment option in patients with advanced colon cancer after positive results of a randomized trial comparing surgery and HIPEC versus palliative treatment alone. Although this trial did not compare the added value of HIPEC to surgery alone, HIPEC for the treatment of peritoneal metastases was in the subsequent years generalized to many other cancer types associated with peritoneal carcinomatosis including epithelial ovarian cancer (EOC). In the meantime, new evidence from prospective randomized trials specifically for EOC-patients emerged, with however contradicting results and several quality aspects that made the interpretation of their findings critical. Moreover, three additional trials in colorectal cancer failed to confirm the previously presumed survival benefit through the implementation of HIPEC in peritoneally disseminated colorectal cancers. Based on a still unclear and inconsistent landscape, the authors conclude that HIPEC should remain within the remit of clinical trials for EOC-patients. Available evidence is not yet sufficient to justify its broad endorsement into the routine clinical practice.
Centre Léon Bérard Lyon France
Department of Gynaecology National Insitute of Oncology Budapest Hungary
Department of Gynecologic Oncology Medical Faculty Mannheim Heidelberg University Mannheim Germany
Department of Gynecology and Obstetrics Ospedale Regionale di Lugano EOC Lugano Switzerland
Department of Obstetrics and Gynaecology CHU de Liège Liège Belgium
Department of Obstetrics and Gynecology Clinica Universidad de Navarra Madrid Spain
Department of Obstetrics and Gynecology Medical University Innsbruck Innsbruck Austria
Department of Obstetrics and Gynecology Paracelsus Medical University Salzburg Salzburg Austria
Department of Obstetrics and Gynecology University Hospital LMU Munich Munich Germany
Departments of Surgery and Cancer Faculty of Medicine Imperial College London London UK
Division of Gynaecological Oncology University Hospitals Leuven Leuven Belgium
Faculty of Biomedical Sciences Università della Svizzera Italiana Lugano Switzerland
Institut Bergonié Bordeaux France
Institut Gustave Roussy Villejuif France
Medical Oncology Department Hospital Universitario La Paz IdiPAZ Madrid Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007025
- 003
- CZ-PrNML
- 005
- 20240423155652.0
- 007
- ta
- 008
- 240412s2024 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bulcan.2023.02.011 $2 doi
- 035 __
- $a (PubMed)36967330
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Harter, Philipp $u Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany. Electronic address: p.harter@kem-med.com
- 245 10
- $a Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer / $c P. Harter, G. Bogner, L. Chiva, D. Cibula, N. Concin, C. Fotopoulou, A. Gonzalez-Martin, F. Guyon, V. Heinzelmann-Schwarz, F. Kridelka, S. Mahner, F. Marmé, C. Marth, P. Morice, Z. Novák, A. Papadia, I. Ray-Coquard, M. Redecha, A. Redondo, R. Schwameis, J. Sehouli, M. Undurraga, T. Van Gorp, I. Vergote
- 520 9_
- $a An international joint statement about the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer was published in 2016, warning about the uncritical use of HIPEC outside controlled studies. This statement has now been updated after the most recent literature was reviewed by the participating study groups and societies. HIPEC became a treatment option in patients with advanced colon cancer after positive results of a randomized trial comparing surgery and HIPEC versus palliative treatment alone. Although this trial did not compare the added value of HIPEC to surgery alone, HIPEC for the treatment of peritoneal metastases was in the subsequent years generalized to many other cancer types associated with peritoneal carcinomatosis including epithelial ovarian cancer (EOC). In the meantime, new evidence from prospective randomized trials specifically for EOC-patients emerged, with however contradicting results and several quality aspects that made the interpretation of their findings critical. Moreover, three additional trials in colorectal cancer failed to confirm the previously presumed survival benefit through the implementation of HIPEC in peritoneally disseminated colorectal cancers. Based on a still unclear and inconsistent landscape, the authors conclude that HIPEC should remain within the remit of clinical trials for EOC-patients. Available evidence is not yet sufficient to justify its broad endorsement into the routine clinical practice.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a epiteliální ovariální karcinom $x patologie $7 D000077216
- 650 _2
- $a hypertermická intraperitoneální peroperační chemoterapie $7 D000084262
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a indukovaná hypertermie $x metody $7 D006979
- 650 12
- $a nádory vaječníků $x farmakoterapie $x patologie $7 D010051
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 651 _2
- $a Rakousko $7 D001317
- 651 _2
- $a Švýcarsko $7 D013557
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bogner, Gerhard $u Department of Obstetrics and Gynecology, Paracelsus Medical University Salzburg, Salzburg, Austria
- 700 1_
- $a Chiva, Luis $u Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain
- 700 1_
- $a Cibula, David $u Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Concin, Nicole $u Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany; Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Fotopoulou, Christina $u Departments of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
- 700 1_
- $a Gonzalez-Martin, Antonio $u Medical Oncology Department Clínica Univerdad de Navarra, Madrid, and Program in Solid Tumours CIMA, Pamplona, Spain
- 700 1_
- $a Guyon, Frederic $u Institut Bergonié, Bordeaux, France
- 700 1_
- $a Heinzelmann-Schwarz, Viola $u University Hospital Basel, Basel, Switzerland
- 700 1_
- $a Kridelka, Frederic $u Department of Obstetrics and Gynaecology, CHU de Liège, Liège, Belgium
- 700 1_
- $a Mahner, Sven $u Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
- 700 1_
- $a Marmé, Frederik $u Department of Gynecologic Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- 700 1_
- $a Marth, Christian $u Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Morice, Philippe $u Institut Gustave-Roussy, Villejuif, France
- 700 1_
- $a Novák, Zoltán $u Department of Gynaecology, National Insitute of Oncology, Budapest, Hungary
- 700 1_
- $a Papadia, Andrea $u Department of Gynecology and Obstetrics, Ospedale Regionale di Lugano EOC, Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
- 700 1_
- $a Ray-Coquard, Isabelle $u Centre Léon Bérard, Lyon, France
- 700 1_
- $a Redecha, Mikuláš $u II. department of gynaecology and obstetrics, University Hospital Bratislava, Comenius University, Bratislava, Slovakia
- 700 1_
- $a Redondo, Andres $u Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
- 700 1_
- $a Schwameis, Richard $u Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Sehouli, Jalid $u Department of Gynecology with Center of Gynecological Oncology,Charité, University Medicine of Berlin, Berlin, Germany
- 700 1_
- $a Undurraga, Manuela $u University Hospital Geneva (HUG), Geneva, Switzerland
- 700 1_
- $a Van Gorp, Toon $u Division of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Vergote, Ignace $u Division of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium
- 773 0_
- $w MED00000917 $t Bulletin du cancer $x 1769-6917 $g Roč. 111, č. 3 (2024), s. 277-284
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36967330 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155648 $b ABA008
- 999 __
- $a ok $b bmc $g 2081185 $s 1216792
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 111 $c 3 $d 277-284 $e 20230324 $i 1769-6917 $m Bulletin du cancer $n Bull Cancer $x MED00000917
- LZP __
- $a Pubmed-20240412
